Chronic inflammatory demyelinating polyneuropathy pipeline is expected to grow in the next few years on account of increasing prevalence of the disease, which is noticed by progressive muscle weakness, loss of deep tendon reflexes, abnormal sensations, etc. According to a study conducted by American Association of Neuromuscular & Electrodiagnostic Medicine, around 40,000 people in the U.S. get affected from the disease, every year. High prevalence of chronic inflammatory demyelinating polyneuropathy is in turn compelling the government agencies and pharmaceutical companies to promote research and development activities for facilitating growth of the pipeline.
Chronic inflammatory demyelinating polyneuropathy is an inflammatory disorder, which affectsthe peripheral nervous system. The diseaseis caused due to the damage of fatty covering myelin sheath that covers and protects nerve fibers.Occurrence of the disease is more common in males as compared to females. Sometimes it is also called as “chronic relapsing polyneuropathy”,whichis closely related to guillain-barre syndrome, because in both the cases the nervous system gets affected. However, in both the cases, the symptoms are not the same for everyone, and can vary from person to person. Some of the common symptoms of the disease includefatigue, pain, weakness, numbness, etc.
Presence of many drugs in the pipeline of various pharmaceutical companies itself shows the need to develop medicines that help in the treatment of chronic inflammatory demyelinating polyneuropathy. Shire Inc., developed Hyqvia (Biological) in collaboration with Bexalta U.S. Inc., for the treatment of chronic inflammatory demyelinating polyneuropathy. Hyqia is subcutaneously administered and is under Phase III stage of clinical trials. I10E is a drug being developed by Laboratoire français de Fractionnement et de Biotechnologies, and is in Phase III stage of clinical trials, which is intravenously administered. I10E is a protein which acts as an immunostimulantthatstimulates the immune system. Fingolimod is another drug developed by Novartis, in collaboration with Mitusbishi Tanabe Pharmaceuticals. Fingolimod is under Phase III stage of clinical trial and is intravenously administered. Fingolimod is a immunomodulator, that targets S1P receptor (S1P receptor functional antagonist).
In 2017, Mitsubishi Tanabe pharmaceutical provided license to Novartis Inc., to conduct clinical trials on fingolimod in Switzerland only. All the drugs (including “fingolimod”, “Hyqvia” & “I10E”) have the efficacy to treat chronic inflammatory demyelinating polyneuropathy. Some of the companies having a pipeline of chronic inflammatory deyelinating polyneuropathy therapeutic include Shire Inc., LB Biotechnologies., Pfizer Inc., Novartis N.V., Eliy-lilly& Company, Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, Abbvie, Inc., Bexalta US, Inc., Mitsubishi Tanabe Pharma Corporation.